CD74 antibody
Quick Overview for CD74 antibody (ABIN3024478)
Target
See all CD74 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Protein G affinity chromatography
-
Immunogen
- SU-DHL-4 lymphoma cells were used as the immunogen for this anti-CD74 antibody.
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
-
The optimal dilution of the anti-CD74 antibody for each application should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL, Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT (1),Prediluted format: incubate for 30 min at RT (2) -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the anti-CD74 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- CD74 (HLA-DR-gamma (CD74))
-
Alternative Name
- CD74
-
Background
- CD74 is a type II transmembrane protein which binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. Anti-CD74 stains predominantly germinal center lymphocytes and B-cell lymphomas, but rarely T-cell lymphomas. Anti-CD74 has been shown to be useful in differentiating atypical fibroxanthoma (-) from malignant fibrous histiocytoma (+).
-
Pathways
- Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints
Target
-